Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

26.25 +0.15 (+0.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 448,972
Open 25.98
Bid (Size) 26.25 (1)
Ask (Size) 28.31 (1)
Prev. Close 26.10
Today's Range 25.91 - 26.34
52wk Range 25.76 - 48.60
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Via Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire

Performance

YTD
-17.97%
-17.97%
1 Month
-10.93%
-10.93%
3 Month
-17.27%
-17.27%
6 Month
-8.50%
-8.50%
1 Year
-42.18%
-42.18%

More News

Read More
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
Via Chartmill
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
Via AB Newswire
Topics Death
Exposures Death
Navigating 4 Analyst Ratings For Pacira BioSciences
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
Preview: Pacira BioSciences's Earnings
Via Benzinga
NASDAQ:PCRX is an undervalued gem with solid fundamentals.
Via Chartmill
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
Via Benzinga
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
From Pacira BioSciences
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
From Pacira BioSciences
Via GlobeNewswire
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
From Pacira BioSciences
Via GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
Via Chartmill
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
From Pacira BioSciences
Via GlobeNewswire
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.